Matching articles for "polyethylene glycol"

Vibrant – An Oral Vibrating Capsule for Chronic Idiopathic Constipation

   
The Medical Letter on Drugs and Therapeutics • May 1, 2023;  (Issue 1675)
The Vibrant orally administered vibrating capsule (Vibrant Gastro), an FDA-cleared medical device, is now available by prescription for treatment of adults with chronic idiopathic constipation (CIC) who...
The Vibrant orally administered vibrating capsule (Vibrant Gastro), an FDA-cleared medical device, is now available by prescription for treatment of adults with chronic idiopathic constipation (CIC) who have not experienced relief of their bowel symptoms by using laxative therapies at the recommended dosage for at least one month. It is the first drug-free treatment to be authorized by the FDA for this indication.
Med Lett Drugs Ther. 2023 May 1;65(1675):65-7 | Show Full IntroductionHide Full Introduction

Drugs for Irritable Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • March 23, 2020;  (Issue 1594)
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.IBS is classified according to the predominant...
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.IBS is classified according to the predominant bowel symptom as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Alterations in the microbiome, stress responses, sensory and motor function of the gut, and host genetic factors may be contributing factors. Since the exact cause of IBS is unknown, the goal of treatment is symptom control.
Med Lett Drugs Ther. 2020 Mar 23;62(1594):41-8 | Show Full IntroductionHide Full Introduction

Prucalopride (Motegrity) for Chronic Idiopathic Constipation

   
The Medical Letter on Drugs and Therapeutics • June 3, 2019;  (Issue 1573)
The FDA has approved the 5-HT4 receptor agonist prucalopride (Motegrity – Shire) for treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride is the only drug currently approved in the US...
The FDA has approved the 5-HT4 receptor agonist prucalopride (Motegrity – Shire) for treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride is the only drug currently approved in the US for treatment of CIC that stimulates colonic peristalsis. It has been available in Europe and Canada for several years.
Med Lett Drugs Ther. 2019 Jun 3;61(1573):86-8 | Show Full IntroductionHide Full Introduction

Plenvu - A Low-Volume PEG-Based Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • January 28, 2019;  (Issue 1564)
The FDA has approved Plenvu (Salix), a polyethylene glycol (PEG)-containing oral powder for reconstitution, for colon cleansing prior to colonoscopy in adults. Plenvu is the first PEG-containing colonoscopy...
The FDA has approved Plenvu (Salix), a polyethylene glycol (PEG)-containing oral powder for reconstitution, for colon cleansing prior to colonoscopy in adults. Plenvu is the first PEG-containing colonoscopy preparation that requires only 1 L of water for dissolution and ingestion of 1 L of clear fluid in addition.
Med Lett Drugs Ther. 2019 Jan 28;61(1564):11-4 | Show Full IntroductionHide Full Introduction

Clenpiq - A Low-Volume Sodium Picosulfate-Based Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • May 21, 2018;  (Issue 1547)
The FDA has approved Clenpiq (Ferring), a low-volume oral solution that contains sodium picosulfate, magnesium oxide, and anhydrous citric acid, for colon cleansing prior to colonoscopy in adults. The...
The FDA has approved Clenpiq (Ferring), a low-volume oral solution that contains sodium picosulfate, magnesium oxide, and anhydrous citric acid, for colon cleansing prior to colonoscopy in adults. The ready-to-drink solution contains the same ingredients as Prepopik, which is supplied as a powder for reconstitution.
Med Lett Drugs Ther. 2018 May 21;60(1547):84-6 | Show Full IntroductionHide Full Introduction

Plecanatide (Trulance) for Chronic Idiopathic Constipation

   
The Medical Letter on Drugs and Therapeutics • April 24, 2017;  (Issue 1519)
The FDA has approved plecanatide (Trulance – Synergy), a guanylate cyclase-C receptor agonist, for treatment of chronic idiopathic constipation (CIC) in adults. Linaclotide (Linzess), another...
The FDA has approved plecanatide (Trulance – Synergy), a guanylate cyclase-C receptor agonist, for treatment of chronic idiopathic constipation (CIC) in adults. Linaclotide (Linzess), another guanylate cyclase-C receptor agonist, and lubiprostone (Amitiza), a chloride channel activator, were approved earlier for treatment of CIC in adults.
Med Lett Drugs Ther. 2017 Apr 24;59(1519):66-8 | Show Full IntroductionHide Full Introduction

Drugs for Irritable Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • September 26, 2016;  (Issue 1504)
Irritable bowel syndrome (IBS) is a common disorder characterized by chronic, intermittent abdominal pain or discomfort and altered bowel habits. It is subtyped according to the predominant bowel symptom as...
Irritable bowel syndrome (IBS) is a common disorder characterized by chronic, intermittent abdominal pain or discomfort and altered bowel habits. It is subtyped according to the predominant bowel symptom as IBS with constipation (IBS-C), IBS with diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Since the exact cause of IBS is unknown, the goal of treatment is symptom control.
Med Lett Drugs Ther. 2016 Sep 26;58(1504):121-6 | Show Full IntroductionHide Full Introduction

Rifaximin (Xifaxan) for Irritable Bowel Syndrome with Diarrhea

   
The Medical Letter on Drugs and Therapeutics • August 3, 2015;  (Issue 1474)
Rifaximin (Xifaxan – Salix), a minimally absorbed oral antibiotic approved previously to treat travelers' diarrhea and to reduce the risk of recurrent hepatic encephalopathy, has now been approved by the...
Rifaximin (Xifaxan – Salix), a minimally absorbed oral antibiotic approved previously to treat travelers' diarrhea and to reduce the risk of recurrent hepatic encephalopathy, has now been approved by the FDA for treatment of irritable bowel syndrome with diarrhea (IBS-D). Eluxadoline (Viberzi – Actavis), a mu-opioid receptor agonist, was also recently approved for IBS-D and will be reviewed in a future issue.
Med Lett Drugs Ther. 2015 Aug 3;57(1474):109-11 | Show Full IntroductionHide Full Introduction

Drugs for Irritable Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • July 1, 2011;  (Issue 107)
Irritable bowel syndrome (IBS) is a common disorder, occurring in up to 15% of the US population; it is 2-2.5 times more frequent in women than in men. IBS is characterized by chronic, intermittent...
Irritable bowel syndrome (IBS) is a common disorder, occurring in up to 15% of the US population; it is 2-2.5 times more frequent in women than in men. IBS is characterized by chronic, intermittent abdominal pain or discomfort accompanied by altered bowel habits. Since the underlying mechanisms of disease remain unclear, management of IBS focuses on symptom control.
Treat Guidel Med Lett. 2011 Jul;9(107):41-6 | Show Full IntroductionHide Full Introduction

Drugs for Irritable Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • March 1, 2006;  (Issue 43)
Irritable bowel syndrome (IBS) is a common disorder, occuring in about 15% of the US population; it is 2-3 times more frequent in women than in men. IBS is characterized by chronic abdominal pain or discomfort...
Irritable bowel syndrome (IBS) is a common disorder, occuring in about 15% of the US population; it is 2-3 times more frequent in women than in men. IBS is characterized by chronic abdominal pain or discomfort and altered bowel habits.
Treat Guidel Med Lett. 2006 Mar;4(43):11-6 | Show Full IntroductionHide Full Introduction

Colonoscopy Preps Addendum

   
The Medical Letter on Drugs and Therapeutics • October 24, 2005;  (Issue 1220)
Since the publication of our article on colonoscopy preparations,1 which compared polyethylene glycol electrolyte solutions (GoLytely, and others) with sodium phosphate (Fleet Phospho-Soda, and others), some...
Since the publication of our article on colonoscopy preparations,1 which compared polyethylene glycol electrolyte solutions (GoLytely, and others) with sodium phosphate (Fleet Phospho-Soda, and others), some readers have told us that we should have included a combination of a magnesium citrate solution with bisacodyl tablets (Evac-QKwik, and others) as an alternative. In one study, such a preparation offered better cleansing and patient tolerance than a sodium phosphate regimen.2

1. Colonoscopy preparations. Med Lett Drugs Ther 2005; 47:53.

2. M Delegge and R Kaplan. Efficacy of bowel preparation with the use of a prepackaged, low fibre diet with a low sodium, magnesium citrate cathartic vs. a clear liquid diet with a standard sodium phosphate cathartic. Aliment Pharmacol Ther 2005; 21:1491.
Med Lett Drugs Ther. 2005 Oct 24;47(1220):88 | Show Full IntroductionHide Full Introduction

Colonoscopy Preparations

   
The Medical Letter on Drugs and Therapeutics • July 4, 2005;  (Issue 1212)
Many patients consider cleansing the bowel in preparation for colonoscopy the most unpleasant part of the procedure. Several methods are...
Many patients consider cleansing the bowel in preparation for colonoscopy the most unpleasant part of the procedure. Several methods are available.
Med Lett Drugs Ther. 2005 Jul 4;47(1212):53-4 | Show Full IntroductionHide Full Introduction